# C_2015206EN.01001101.xml

| 23.6.2015 | EN | Official Journal of the European Union | C 206/11 |
| --- | --- | --- | --- |

23.6.2015

EN

Official Journal of the European Union

C 206/11

---

Prior notification of a concentration

(Case M.7583 — CSL Limited/Novartis Influenza Vaccines Business)

(Text with EEA relevance)

(2015/C 206/07)

| 1. | On 12 June 2015, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which CSL Limited (‘CSL’, Australia) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of Novartis Influenza Vaccines Business (‘Target’, Switzerland) by way of purchase of shares and assets. |
| --- | --- |

1.

On 12 June 2015, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which CSL Limited (‘CSL’, Australia) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of Novartis Influenza Vaccines Business (‘Target’, Switzerland) by way of purchase of shares and assets.

1

| 2. | The business activities of the undertakings concerned are:






  — | CSL is a pharmaceutical company active in worldwide research, development, manufacturing and marketing of biotherapies, vaccines (via its subsidiary bioCSL) and other pharmaceuticals, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

CSL is a pharmaceutical company active in worldwide research, development, manufacturing and marketing of biotherapies, vaccines (via its subsidiary bioCSL) and other pharmaceuticals,

| — | the Target is Novartis’ human influenza vaccines business, which manufactures and sells influenza vaccines primarily in the United States, the EEA and Argentina. Novartis is a diversified healthcare company. In Europe, its business includes Novartis Pharmaceuticals, Alcon (eye care medicines) and Sandoz (generic medicines). |
| --- | --- |

—

the Target is Novartis’ human influenza vaccines business, which manufactures and sells influenza vaccines primarily in the United States, the EEA and Argentina. Novartis is a diversified healthcare company. In Europe, its business includes Novartis Pharmaceuticals, Alcon (eye care medicines) and Sandoz (generic medicines).

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.7583 — CSL Limited/Novartis Influenza Vaccines Business to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.7583 — CSL Limited/Novartis Influenza Vaccines Business to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

---